Euractiv (Advocacy Lab)
EU Perspectives
European Biotechnology Magazine
APM Market Access
EU PERSPECTIVES - The biggest overhaul of Europe's pharmaceutical law in two decades is to arrive this autumn, with a two-year transition. Lawyer Hein van den Bos explains to EU Perspectives what changes, what the debate missed, and why anything now in development is already affected. Read more
EURACTIV - Belgium does not spend unusually little on medicines compared with its larger neighbours. It spends the money badly, argues Professor Walter Van Dyck. The economist says Belgium cuts prices hard to stay within a tight budget today, then pays later in lost innovation. Read more
EU PERSPECTIVES - New medicines are reaching Europe later than the US. A recent study says two separate policies are to blame, and that the damage is the worst when they meet. Read more
EU PERSPECTIVES - A cancer treatment can clear Europe-wide approval, yet patient access still varies enormously from one country to the next. The difference is as much as three years, Isabel Rubio, the president of the European Cancer Organisation tells EU Perspectives. Read more
